Mice immunized with Sindbis virus, strains HR (heat-resistant) or AR339, by a dual injection given intracerebrally (i.c.) and intraperitoneally (i.p.) at day zero, were cross-protected from challenge at day IO with Semliki Forest virus (SFV). Neutralizing and haemagglutination-inhibition antibodies to Sindbis are detected in high titre by day 6 after immunization but no cross-reacting antibodies to SFV were found up to day 42. Immunized mice that were challenged with SFV showed an 8 to IO day delay in the appearance of antibody to SFV compared to mice that were sham-inoculated. Thus, cross-protection in Sindbis-immunized animals was correlated with a temporary suppression of antibody formation to the challenge virus (SFV), while the appearance of high titre antibody to SFV in shamimmunized mice after challenge with SFV did not protect.
INTRODUCTION
Immunization of animals with alpha-or flaviviruses is known to cross-protect against challenge by other members within the group. This cross-protection occurs in the absence of detectable cross-neutralizing antibody (Porterfield, I962; Casals, 1963; Hearn & Rainey, I963; Chamberlain, 1968; Cole & McKinney, i971; Brown & Officer, 1975) . We have been studying the mechanisms of cross-protection against the alphavirus, Semliki Forest virus (SFV), in mice immunized with Sindbis virus (Peck et al. 1975 (Peck et al. , 1979a King et al. 1977; Latif et al. 2979) . We found that T-cell-mediated immunity plays a major role in the crossprotection, because recipient mice were protected from challenge when they received adoptive transfers of T-cell-enriched populations of spleen cells from an immunized donor (Peck et al. 1975 (Peck et al. , 2979a , because heterologous cytotoxicity to SFV-infected cells could be shown in vitro with spleen cells from mice immunized with Sindbis virus (Peck et al. I979b) and because T-cell-deficient nude mice showed significantly lower cross-protection than control littermates (Latif et al. i979 ). In addition, Mullbacher et al. (1979) reported that cytotoxic T-cells from animals immunized with alphaviruses (Bebaru, Sindbis and SFV) cross-react against virus-infected target cells although antisera showed virus specificity in their ability to block the cell-mediated cytolysis. One of the intriguing features of our in vitro findings was that concomitant with cross-protection there appeared to be a suppression of homologous cytotoxicity while a marked increase in heterologous cytotoxicity was noted following a second immunizing dose of Sindbis virus (Peck et al. I979b ).
To explain this observation, we considered the phenomenon of immune deviation (Parish, 1972) in which there is an inverse relationship between cell-mediated and humoral immunity dependent on various immunization conditions. Some of these conditions could include the relative amount of antigen available to generate immunity and whether the antigen is present only on virus-infected cells where it would presumably be associated with cell membrane components.
In the present report, we focus on the humoral response since we assumed that with immune deviation, antibody production might be depressed during T-cell-mediated crossprotection. We found that there is a temporary suppression in the production of neutralizing and haemagglutination-inhibiting antibodies to the challenge virus when mice are crossprotected.
METHODS
Animals. HA/ICR male mice were obtained from three sources for three experiments that were repeats with similar results. These sources were: Blue Spruce Animal Farms (Gardner Altamont, N.Y., U.S.A.); Sprague-Dawley (Madison, Wis., U.S.A.); and Cumberland View Farms (Clinton, Tenn., U.S.A.). All mice were 6 weeks old at the time of the first immunization.
Viruses. A description of the HR strain of Sindbis virus, together with the methods of cultivation and titration in chick embryo (CE) fibroblast culture, has been reported previously (Brown, I963; Burge & Pfefferkorn, I966; Schluter et aL I974) . Stocks of virus contained the following p.f.u./ml: Sindbis virus, strain HR, IO9; Sindbis virus, strain AR339, originally obtained from J. Casals, 5 × Io9; and SFV, originally from W. P. Allen, 3 x io 7.
Immunization and challenge. Animals were immunized with Sindbis virus (HR or AR339) by a dual injection of IO 7 p.f.u./animal intraperitoneally (i.p.) and lO 6 p.f.u, intracerebrally (i.c.). Control animals were given spent tissue culture medium in diluent only (beef heart infusion broth, BHI, Difco). Ten days later, the animals were challenged with 25 p.f.u, of SFV i.c. which were equivalent to IO median intracerebral 5o~o lethal doses (MICLDs0) as titrated in non-immunized mice. Immunized control animals were given IOO MICLDs0 of virulent Sindbis HRB (Boone & Brown, I976) brain passaged in suckling mice, to determine homologous protection. SFV was given to sham-inoculated animals as non-immunized controls. Animal deaths were recorded twice daily and survivors were randomly selected for experimentation. Usually IO mice from any group were killed every 2 days for 30 days. The blood from a group was pooled, serum collected and stored at -5 ° °C until assayed.
Neutralization test. The plaque reduction neutralization test was used to assay virus neutralizing antibody (Dulbecco & Vogt, 1953) . Briefly, serial twofold dilutions of serum in 0"4 ml/BHI were mixed with an equal vol. of BHI containing 6oo p.f.u, of virus. The mixture was incubated at ambient temperature for 60 min, then 0.2 ml of each dilution was added to CE monolayers in 60 × I5 mm plastic Petri dishes (Falcon Plastics, Oxnard, Calif., U.S.A.). After 30 min, the monolayers were overlaid with 3 to 4 ml lactalbumin hydrolysate agar. The agar contained o.1~ yeast extract, IO~ Hanks' balanced salt solution, I-1~ agar, o. I4~ o sodium bicarbonate, 125 g/ml streptomycin, 125 units/ml penicillin and was supplemented with 3 mg/ml L-cysteine and 2.55 mg/ml L-histidine (Zebovitz, 1965) . Following incubation for 48 h at 37 °C in 5 ~o COs, each plate was stained with 3 to 4 ml of a solution containing 0-03 mg neutral red dye/ml, incubated for 3 to 4 h and the plaques counted.
Haemagglutination-inhibition test. Haemagglutination and haemagglutination-inhibition assays were carried out according to the method of Clarke & Casals (1958) as modified for microtitre plates. 
RESULTS

Cross-protection
We, like others, have demonstrated that immunization with Sindbis virus, strains AR339 or HR, confers cross-protection to challenge with SFV (Casals, I963; Hearn & Rainey, t963; Brand & Allen, I964; Peck et aL I975) . In the present work, a dual injection of Sindbis virus AR339 given i.c. and i.p. on the same day was shown to be an effective immunization schedule (Table I) . Two parameters of protection are given, namely percentage survival and average day of death (ADD), based on our previous work (Latif et al. I979) . Using this regimen, 859/0 of the animals survived challenge with IO MICLDso of SFV with an ADD of 9"8, whereas lOp K of sham-immunized animals succumbed (ADD of 7"0). Similar results were obtained (86~ o protection; ADD of 5"5) with animals immunized with Sindbis virus AR339 and challenged with lO 7 p.f.u./mouse i.c. of the homologous virus.
Neutralization titres
Following immunization with Sindbis virus, sera were collected at various times from mice selected at random. In Fig. I , the neutralization titres of pooled sera (IO animals) are plotted at each time point. Neutralizing antibody to Sindbis virus was detected by day 4 and reached near peak titres by day lO (Fig. I a) . However, neutralizing antibody to SFV could not be detected in these animals and, furthermore, neutralizing antibody to Sindbis was undetectable in sham-immunized mice that were challenged with SFV. These results confirm other reports that no cross-neutralizing antibody is produced between these two viruses (Casals, I963; Hearn & Rainey, I963; Brand & Allen, I964) . Fig. I (b) presents the distinctive feature of these experiments, which is that mice immunized with Sindbis virus and protected from challenge with SFV do not show neutralizing antibody to SFV until Io days after the time when antibody to SFV was detectable in shamimmunized and challenged mice. Thus, the presence of detectable neutralizing antibody to the challenge virus (SFV) did not correlate with cross-protection. The formation of such antibody following the injection of SFV did not provide protection in sham-immunized animals.
Haemagglutination-inhibition (HA1) titres
Certain antibodies to alphaviruses may be detected by their ability to inhibit the haemagglutination of gander erythrocytes (Clarke & Casals, I958 (Clarke & Casals, I958) . All assays were done in triplicate and repeated. those detectable by the neutralization technique since, following prolonged immunization, low levels of cross-reactive HAI antibody can be demonstrated (King et aL 1977) . However, the immunization schedule used in the present study, did not elicit cross-HA1 antibody. This is shown in Fig. 2 . High levels of Sindbis virus-spe6ific HA1 antibody were found by day Io after Sindbis virus immunization and remained high until day 4 o.
On the other hand, animals that were immunized with Sindbis virus and subsequently challenged on day IO with SFV did not show a detectable HA1 titre to SFV until day z2 (Fig. 2b) while sham-immunized mice challenged with SFV produced HA1 antibody by day 16. This delay in appearance of HA1 antibody corresponds to the delay observed for neutralizing antibody (Fig. I ) which is coincident with cross-protection.
It should be noted that the experiments were done three times with similar results using the three sources of animals given in Methods and using Sindbis virus, strain HR or AR339. Each assay was repeated at least once and run in triplicate each time. The results represent observations with over 3600 mice. The most significant finding in this study is the temporary suppression of the humoral response to the challenge virus (SFV) in mice immunized with Sindbis virus. This delayed response in both neutralizing and HA1 antibody production to SFV is coincident with cross-protection. We propose, therefore, that there is an inverse relationship between cross-protection and the humoral response to the challenge virus.
We consider the inverse relationship to be significant in the light of work which indicates that cell-mediated immunity (CMI) probably plays an important role in cross-protection among alphaviruses (Peck et al. 1975, I979a, b; Latif et al. I979) , and in light of a phenomenon called immune deviation described in non-viral systems (Parish, 1972; Gershon, 1975) .
With respect to the role of CMI in cross-protection, the data were obtained from a variety of different but related protocols that are consistent and confirmatory with our conclusions on the role of CMI in cross-protection. Those protocols involved the following: partially outbred HA/ICR mice (Peck et al. I975) , several strains of inbred mice (Peck et aL I979a), passive cell transfer experiments (Peck et al. 1975 (Peck et al. , 1979 , Swiss nude mice and their control littermates (Latif et al. 1979) and cytotoxicity experiments in cell culture (Peck et al. I979b) , i.p. or i.c. routes of immunization or challenge (Peck et al. 1975; I979 a, b; Latif et al. 1979) , etc. In random samples taken for antibody determinations (C. J. Wust & A. Brown, unpublished results) we noticed an absence of antibody when lymphocyte cytotoxicity was high (Peck et al. 1979b ) . This led to the present detailed study, especially in the context of immune deviation reported by others in non-viral systems. Parish (1972) reviewed evidence to support the concept of an inverse relationship between CMI, as measured by delayed type hypersensitivity (DTH) reactions, and antibody formation which he called immune deviation. In detailed studies, it was shown that the passive administration of antibody to Salmonella adelaide flagellin, polymerized flagellin and sheep erythrocytes suppressed specific antibody formation in recipient rats and this coincided with enhanced DTH (Liew & Parish, 1972 a, b) . The regulation of which type of immune response develops, may reside in the relative association of antigen bound to macrophages (Liew & Parish, I972c) and T-cell subpopulations. Gershon (1975) suggested that the higher the level of activity of immune cells, the greater is the feedback regulation of certain T-cell subpopulations. Consistent with this, it would appear that high levels of antibody to Sindbis virus are suppressive (temporarily) for the humoral responses to the related challenge SFV. In the absence of antibody to SFV, and on the basis of our previous in vitro CMI results (Peck et al. 1979b) , and adoptive transfer experiments (Peck et al. 1975, I979a) , we propose that specific CMI to SFV is generated rapidly, and at a sustained level high enough to protect mice from the challenge virus.
The delayed appearance of antibody to SFV in Sindbis virus-immunized mice in the present study is coincident with enhanced CMI as reported previously (Peck et al. I979b) , and cross-protection is probably best explained by immunity directed to infected cells. CMI has been found to be particularly important in infections with viruses in mice that mature at the cell membrane (Bloom & Rager-Zisman, 1975 ) and usually involves cytotoxic T-cells specific for cell-associated antigens on alphavirus-infected cells (Kraaijeveld et al. I979a, b) . It is clear that cell-bound virus antigens may be somewhat different from the antigens on free virions. In this context, it is known that larger precursor proteins and/or peptides that are not incorporated into free virions are found at the cell surface of Sindbis virus-and SFV-infected cells (Sefton et aL 1973) .
Thus we interpret the present data to indicate that there is a correlation between the delayed appearance of antibody and cross-protection. In turn, we have related these to the time of detection of CMI by other in vivo and in vitro experiments carried out in our laboratory (Peck et aL I975, I979a, b) . A. SMITH-OWIRODU AND OTHERS Alternative explanations to CMI in cross-protection among togaviruses (e.g. more rapid mobilization of the antibody to the challenge virus, a humoral factor that is not interferon, interference mechanisms, etc.) have been previously reviewed by us (Peck et al. I975) and were considered as unlikely. Non-specific interference mechanisms were eliminated largely because they were almost always transient, lasting only a few days. However, a non-sPecific mechanism has been proposed in which enhanced resistance to a flavivirus (Langat) was observed after immunization with the alphaviruses Sindbis virus or SFV (Oaten et al. 1976) . Such resistance correlated with relatively high virus concentrations in the mouse brain and an interference was postulated based on a competition of the alphavirus and the flavivirusfor the same target cells. This hypothesis is certainly viable, but considerably more evidence is needed to substantiate it. We favour the evidence that strongly suggests a role for CMI in cross-protection within the alphavirus group. Although we have not used Langat virus, we have challenged mice with vesicular stomatitis and vaccinia viruses and found no crossprotection compared to controls (Peck et al. I975, after adoptive cell transfer; Peck, 1974 , after active immunization). An alternative explanation for the delayed appearance of antibody reported in the present paper can be derived from the interference of challenge virus multiplication postulated by Oaten et al. (1976) in which they point out that the original virus persists for 5 weeks and they discuss possible persistence of virus (and interference) for even longer periods. We argue against this explanation because in our data, we find a delay varying from 8 to io days, but following this delay, the neutralizing and HAI titres are higher than in sham-immunized controls. The extensive rise in antibody and the time it occurred would be unlikely if interference persisted as reported.
On the basis of our studies to date, we suggest that successful vaccination procedures for cross-protection among alphaviruses may require an enhancement of immune deviation (enhanced CMI coupled with suppressed antibody synthesis) to the challenge virus. A second suggestion would be to use a live, attenuated alphavirus vaccine so that advantage is taken of any specific non-virion, cell membrane-associated antigens that might contribute to protection.
